-
1
-
-
56949101509
-
Comparative associations of adiposity measures with cardiometabolic risk burden in asymptomatic subjects
-
Dervaux, N.; Wubuli, M.; Megnien, J.L.; Chironi, G.; Simon, A. Comparative associations of adiposity measures with cardiometabolic risk burden in asymptomatic subjects. Atherosclerosis, 2008, 201, 413-417.
-
(2008)
Atherosclerosis
, vol.201
, pp. 413-417
-
-
Dervaux, N.1
Wubuli, M.2
Megnien, J.L.3
Chironi, G.4
Simon, A.5
-
2
-
-
79960853510
-
Vascular biology of metabolic syndrome
-
Vykoukal, D.; Davies, M.G. Vascular biology of metabolic syndrome. J. Vasc. Surg., 2011, 54(3), 819-831.
-
(2011)
J. Vasc. Surg
, vol.54
, Issue.3
, pp. 819-831
-
-
Vykoukal, D.1
Davies, M.G.2
-
3
-
-
77956417119
-
Predictors of insulin resistance in the obese with metabolic syndrome
-
Manu, P.; Tsang, J.; Napolitano, B.A.; Lesser, M.L.; Correll, C.U. Predictors of insulin resistance in the obese with metabolic syndrome. Eur. J. Intern. Med., 2010, 21, 409-413.
-
(2010)
Eur. J. Intern. Med
, vol.21
, pp. 409-413
-
-
Manu, P.1
Tsang, J.2
Napolitano, B.A.3
Lesser, M.L.4
Correll, C.U.5
-
4
-
-
67651121708
-
The role of PPARs in modulating cardiac metabolism in diabetes
-
Holness, M.J.; Samsuddin, S.; Sugden, M.C. The role of PPARs in modulating cardiac metabolism in diabetes. Pharmacol. Res., 2009, 60, 185-194.
-
(2009)
Pharmacol. Res
, vol.60
, pp. 185-194
-
-
Holness, M.J.1
Samsuddin, S.2
Sugden, M.C.3
-
5
-
-
79251492672
-
Prevalence of the metabolic syndrome in elderly and middle-aged Japanese
-
Arai, H.; Yamamoto, A.; Matsuzawa, Y.; Saito, Y.; Yamada, N.; Oikawa, S.; Mabuchi, H.; Tamio Teramoto, T.; Sasaki, J.; Nakaya, N.; Itakura, H.; Ishikawa, Y.; Ouchim, Y.; Horibe, H.; Kita, T. Prevalence of the metabolic syndrome in elderly and middle-aged Japanese. J. Clinl. Gerontol. Geriatr., 2010, 1, 42-47.
-
(2010)
J. Clinl. Gerontol. Geriatr
, vol.1
, pp. 42-47
-
-
Arai, H.1
Yamamoto, A.2
Matsuzawa, Y.3
Saito, Y.4
Yamada, N.5
Oikawa, S.6
Mabuchi, H.7
Tamio Teramoto, T.8
Sasaki, J.9
Nakaya, N.10
Itakura, H.11
Ishikawa, Y.12
Ouchim, Y.13
Horibe, H.14
Kita, T.15
-
6
-
-
77955094662
-
Prevalence and risk factors of metabolic syndrome among Asian Indians: A community survey
-
Ravikiran, M.; Bhansali, A.; Ravikumar, P.; Bhansali, S.; Dutta, P.; Thakur, J.S.; Sachdeva, N.; Bhadada, S.; Walia, R. Prevalence and risk factors of metabolic syndrome among Asian Indians: a community survey. Diabetes Res. Clin. Pract., 2010, 89, 181-188.
-
(2010)
Diabetes Res. Clin. Pract
, vol.89
, pp. 181-188
-
-
Ravikiran, M.1
Bhansali, A.2
Ravikumar, P.3
Bhansali, S.4
Dutta, P.5
Thakur, J.S.6
Sachdeva, N.7
Bhadada, S.8
Walia, R.9
-
7
-
-
84874304580
-
Exploring the Complexity of Cardiometabolic Risk in Women
-
[Epub ahead of print]
-
Robins, J.L.; McCain, N.L.; Elswick, R.K. Jr. Exploring the Complexity of Cardiometabolic Risk in Women. Biol. Res. Nurs., 2011, [Epub ahead of print].
-
(2011)
Biol. Res. Nurs
-
-
Robins, J.L.1
McCain, N.L.2
Elswick Jr., R.K.3
-
8
-
-
33846365989
-
Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies
-
Gami, A.S.; Witt, B.J.; Howard, D.E.; Erwin, P.J.; Gami, L.A.; Somers, V.K.; Montori, V.M. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol., 2007, 49, 403-414.
-
(2007)
J. Am. Coll. Cardiol
, vol.49
, pp. 403-414
-
-
Gami, A.S.1
Witt, B.J.2
Howard, D.E.3
Erwin, P.J.4
Gami, L.A.5
Somers, V.K.6
Montori, V.M.7
-
9
-
-
79958065049
-
Identification and management of cardiometabolic risk in Canada: A position paper by the cardiometabolic risk working group (executive summary)
-
Cardiometabolic Risk Working Group: Executive Committee
-
Cardiometabolic Risk Working Group: Executive Committee.; Leiter, L.A.; Fitchett, D.H.; Gilbert, R.E.; Gupta, M.; Mancini, G.B.; McFarlane P.A.; Ross, R.; Teoh, H.; Verma, S. Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). Can. J. Cardiol., 2011, 27, 124-131.
-
(2011)
Can. J. Cardiol
, vol.27
, pp. 124-131
-
-
Leiter, L.A.1
Fitchett, D.H.2
Gilbert, R.E.3
Gupta, M.4
Mancini, G.B.5
McFarlane, P.A.6
Ross, R.7
Teoh, H.8
Verma, S.9
-
10
-
-
52949130244
-
The concept of cardiometabolic risk: Bridging the fields of diabetology and cardiology
-
Després, J.P.; Cartier, A.; Côté, M.; Arsenault, B.J. The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med., 2008, 40, 514-523.
-
(2008)
Ann Med
, vol.40
, pp. 514-523
-
-
Després, J.P.1
Cartier, A.2
Côté, M.3
Arsenault, B.J.4
-
11
-
-
72449152949
-
Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: Results from large scale efficacy trials
-
Horton, E.S. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. Obesity (Silver Spring), 2009, 17(Suppl. 3), S43-S48.
-
(2009)
Obesity (Silver Spring)
, vol.17
, Issue.SUPPL. 3
-
-
Horton, E.S.1
-
12
-
-
47349107995
-
Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders
-
Cho, M.C.; Lee, K.; Paik, S.G.; Yoon, D.Y. Peroxisome proliferators-activated receptor (PPAR) modulators and metabolic disorders. PPAR Res., 2008, 2008, 679137.
-
(2008)
PPAR Res
, vol.2008
, pp. 679137
-
-
Cho, M.C.1
Lee, K.2
Paik, S.G.3
Yoon, D.Y.4
-
13
-
-
67651154149
-
The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome
-
Huang, T.H.; Teoh, A.W.; Lin, B.L.; Lin, D.S.; Roufogalis, B. The role of herbal PPAR modulators in the treatment of cardiometabolic syndrome. Pharmacol. Res., 2009, 60, 195-206.
-
(2009)
Pharmacol. Res
, vol.60
, pp. 195-206
-
-
Huang, T.H.1
Teoh, A.W.2
Lin, B.L.3
Lin, D.S.4
Roufogalis, B.5
-
14
-
-
23944443718
-
Regulation of gene transcription by botanicals: Novel regulatory mechanisms
-
Shay, N.F.; Banz, W.J. Regulation of gene transcription by botanicals: novel regulatory mechanisms. Annu. Rev. Nutr., 2005, 25, 297-315.
-
(2005)
Annu. Rev. Nutr
, vol.25
, pp. 297-315
-
-
Shay, N.F.1
Banz, W.J.2
-
15
-
-
47949094965
-
Integration of metabolism and inflammation by lipid-activated nuclear receptors
-
Bensinger, S.J.; Tontonoz, P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature, 2008, 454, 470-477.
-
(2008)
Nature
, vol.454
, pp. 470-477
-
-
Bensinger, S.J.1
Tontonoz, P.2
-
16
-
-
0033793133
-
Peroxisome proliferatoractivated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation
-
Chinetti, G.; Fruchart, J.C.; Staels, B. Peroxisome proliferatoractivated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res., 2000, 49, 497-505.
-
(2000)
Inflamm. Res
, vol.49
, pp. 497-505
-
-
Chinetti, G.1
Fruchart, J.C.2
Staels, B.3
-
17
-
-
11144310564
-
An overview on biological mechanisms of PPARs
-
Kota, B.P.; Huang, T.H.; Roufogalis, B.D. An overview on biological mechanisms of PPARs. Pharmacol. Res., 2005, 51, 85-94.
-
(2005)
Pharmacol. Res
, vol.51
, pp. 85-94
-
-
Kota, B.P.1
Huang, T.H.2
Roufogalis, B.D.3
-
18
-
-
33751533892
-
Wahli International Union of Pharmacology LXI. Peroxisome proliferator-activated receptors
-
Michalik, L.; Auwerx, J.; Berger, J.P.; Chatterjee, V.K.; Glass, C.K.; Gonzalez, F.J.; Grimaldi PA, Kadowaki, T.; Lazar, M.A.; O'Rahilly, S.; Palmer, C.N.; Plutzky, J.; Reddy, J.K.; Spiegelman, B.M.; Staels, B.; Wahli, W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev., 2006, 58, 726-741.
-
(2006)
Pharmacol. Rev
, vol.58
, pp. 726-741
-
-
Michalik, L.1
Auwerx, J.2
Berger, J.P.3
Chatterjee, V.K.4
Glass, C.K.5
Gonzalez, F.J.6
Grimaldi, P.A.7
Kadowaki, T.8
Lazar, M.A.9
O'Rahilly, S.10
Palmer, C.N.11
Plutzky, J.12
Reddy, J.K.13
Spiegelman, B.M.14
Staels, B.15
-
19
-
-
0034668205
-
Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis
-
Neve, B.P.; Fruchart, J.C.; Staels, B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem. Pharmacol., 2000. 60, 1245-1250.
-
(2000)
Biochem. Pharmacol
, vol.60
, pp. 1245-1250
-
-
Neve, B.P.1
Fruchart, J.C.2
Staels, B.3
-
20
-
-
42749100646
-
Selective Modulators of PPARgamma Activity: Molecular Aspects Related to Obesity and Side-Effects
-
Zhang F, Lavan BE, Gregoire FM. Selective Modulators of PPARgamma Activity: Molecular Aspects Related to Obesity and Side-Effects. PPAR Res., 2007, 32696.
-
(2007)
PPAR Res
, pp. 32696
-
-
Zhang, F.1
Lavan, B.E.2
Gregoire, F.M.3
-
21
-
-
0030877565
-
Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and-2 isoforms and influence of insulin
-
Werman, A.; Hollenberg, A.; Solanes, G.; Bjorbaek, C.; Vidal-Puig, A.J.; Flier, J.S. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and-2 isoforms and influence of insulin. J. Biol. Chem., 1997, 272, 20230-20235.
-
(1997)
J. Biol. Chem
, vol.272
, pp. 20230-20235
-
-
Werman, A.1
Hollenberg, A.2
Solanes, G.3
Bjorbaek, C.4
Vidal-Puig, A.J.5
Flier, J.S.6
-
22
-
-
0036183630
-
The mechanisms of action of PPARs
-
Berger, J.; Moller, D.E. The mechanisms of action of PPARs. Annu. Rev. Med., 2002, 53, 409-435.
-
(2002)
Annu. Rev. Med
, vol.53
, pp. 409-435
-
-
Berger, J.1
Moller, D.E.2
-
23
-
-
77958060003
-
Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease
-
Azhar, S. Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol., 2010, 6, 657-691.
-
(2010)
Future Cardiol
, vol.6
, pp. 657-691
-
-
Azhar, S.1
-
24
-
-
38549127422
-
Suppression of pro-inflammatory adhesion molecules by PPARdelta in human vascular endothelial cells
-
DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators
-
DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators.; Gerstein, H.C.; Yusuf, S.; Bosch, J.; Pogue, J.; Sheridan, P.; Dinccag, N.; Hanefeld, M.; Fan, Y.; Wang, Y.; Tang, Z.; Zhang, H.; Qin, X.; Zhu, Y.; Guan, Y.; Wang, X.; Staels, B.; Chien, S.; Wang, N. Suppression of pro-inflammatory adhesion molecules by PPARdelta in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 315-321.
-
(2008)
Arterioscler. Thromb. Vasc. Biol
, vol.28
, pp. 315-321
-
-
Gerstein, H.C.1
Yusuf, S.2
Bosch, J.3
Pogue, J.4
Sheridan, P.5
Dinccag, N.6
Hanefeld, M.7
Fan, Y.8
Wang, Y.9
Tang, Z.10
Zhang, H.11
Qin, X.12
Zhu, Y.13
Guan, Y.14
Wang, X.15
Staels, B.16
Chien, S.17
Wang, N.18
-
25
-
-
26244453309
-
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): A randomised controlled trial
-
PROactive investigators
-
Dormandy, J.A.; Charbonnel, B.; Eckland, D.J.; Erdmann, E.; Massi-Benedetti, M.; Moules, I.K.; Skene, A.M.; Tan, M.H.; Lefèbvre, P.J.; Murray, G.D.; Standl, E.; Wilcox, R, G.; Wilhelmsen, L.; Betteridge, J.; Birkeland, K.; Golay, A.; Heine, R.J.; Korányi, L.; Laakso, M.; Mokán, M.; Norkus, A.; Pirags, V.; Podar, T.; Scheen, A.; Scherbaum, W.; Schernthaner, G.; Schmitz, O.; Skrha, J.; Smith, U.; Taton, J.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet, 2005, 366, 1279-1289.
-
(2005)
Lancet
, vol.366
, pp. 1279-1289
-
-
Dormandy, J.A.1
Charbonnel, B.2
Eckland, D.J.3
Erdmann, E.4
Massi-Benedetti, M.5
Moules, I.K.6
Skene, A.M.7
Tan, M.H.8
Lefèbvre, P.J.9
Murray, G.D.10
Standl, E.11
Wilcox, R.G.12
Wilhelmsen, L.13
Betteridge, J.14
Birkeland, K.15
Golay, A.16
Heine, R.J.17
Korányi, L.18
Laakso, M.19
Mokán, M.20
Norkus, A.21
Pirags, V.22
Podar, T.23
Scheen, A.24
Scherbaum, W.25
Schernthaner, G.26
Schmitz, O.27
Skrha, J.28
Smith, U.29
Taton, J.30
more..
-
26
-
-
33845405222
-
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
-
ADOPT Study Group
-
Kahn, S.E.; Haffner, S.M.; Heise, M.A.; Herman, W.H.; Holman, R.R.; Jones, N.P.; Kravitz, B.G.; Lachin, J.M.; O'Neill, M.C.; Zinman, B.; Viberti, G.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl J Med., 2006, 355, 2427-2443.
-
(2006)
N. Engl J Med
, vol.355
, pp. 2427-2443
-
-
Kahn, S.E.1
Haffner, S.M.2
Heise, M.A.3
Herman, W.H.4
Holman, R.R.5
Jones, N.P.6
Kravitz, B.G.7
Lachin, J.M.8
O'Neill, M.C.9
Zinman, B.10
Viberti, G.11
-
27
-
-
34648832073
-
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials
-
Lago, R.M.; Singh, P.P.; Nesto, R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet, 2007, 370, 1129-1136.
-
(2007)
Lancet
, vol.370
, pp. 1129-1136
-
-
Lago, R.M.1
Singh, P.P.2
Nesto, R.W.3
-
28
-
-
67149146438
-
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
-
RECORD Study Team
-
Home, P.D.; Pocock, S.J.; Beck-Nielsen, H.; Curtis, P.S.; Gomis, R.; Hanefeld, M.; Jones, N.P.; Komajda, M.; McMurray, J.J.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet, 2009, 373, 2125-2135.
-
(2009)
Lancet
, vol.373
, pp. 2125-2135
-
-
Home, P.D.1
Pocock, S.J.2
Beck-Nielsen, H.3
Curtis, P.S.4
Gomis, R.5
Hanefeld, M.6
Jones, N.P.7
Komajda, M.8
McMurray, J.J.9
-
29
-
-
79953203593
-
Comparative cardiovascular effects of thiazolidinediones: Systematic review and meta-analysis of observational studies
-
Loke, Y.K.; Kwok, C.S.; Singh, S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ, 2011, 342, d1309.
-
(2011)
BMJ
, vol.342
-
-
Loke, Y.K.1
Kwok, C.S.2
Singh, S.3
-
30
-
-
77649144555
-
Pioglitazone: Side effect and safety profile
-
Shah, P.; Mudaliar, S. Pioglitazone: side effect and safety profile. Expert Opin. Drug Saf., 2010, 9, 347-354
-
(2010)
Expert Opin. Drug Saf
, vol.9
, pp. 347-354
-
-
Shah, P.1
Mudaliar, S.2
-
31
-
-
77956335013
-
Potential remains for PPAR-targeted drugs
-
Jones, D. Potential remains for PPAR-targeted drugs. Nat. Rev. Drug Discov., 2010, 668-669.
-
(2010)
Nat. Rev. Drug Discov
, pp. 668-669
-
-
Jones, D.1
-
32
-
-
77954667427
-
Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: Pioglitazone versus rosiglitazone
-
Simó, R.; Rodriguez, A.; Caveda, E. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone. Curr. Drug Saf., 2010, 5, 234-244.
-
(2010)
Curr. Drug Saf
, vol.5
, pp. 234-244
-
-
Simó, R.1
Rodriguez, A.2
Caveda, E.3
-
33
-
-
34548590934
-
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials
-
Lincoff, A.M.; Wolski, K.; Nicholls, S.J.; Nissen, S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA, 2007, 298, 1180-1188.
-
(2007)
JAMA
, vol.298
, pp. 1180-1188
-
-
Lincoff, A.M.1
Wolski, K.2
Nicholls, S.J.3
Nissen, S.E.4
-
34
-
-
41649084422
-
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial
-
PERISCOPE Investigators
-
Nissen, SE.; Nicholls, S.J.; Wolski, K.; Nesto, R.; Kupfer, S.; Perez, A.; Jure, H.; De Larochellière, R.; Staniloae, C.S.; Mavromatis, K.; Saw, J.; Hu, B.; Lincoff, A.M.; Tuzcu, EM.; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA, 2008, 299, 1561-1573.
-
(2008)
JAMA
, vol.299
, pp. 1561-1573
-
-
Nissen, S.E.1
Nicholls, S.J.2
Wolski, K.3
Nesto, R.4
Kupfer, S.5
Perez, A.6
Jure, H.7
de Larochellière, R.8
Staniloae, C.S.9
Mavromatis, K.10
Saw, J.11
Hu, B.12
Lincoff, A.M.13
Tuzcu, E.M.14
-
35
-
-
79952062014
-
Pioglitazone and alogliptin combination therapy in type 2 diabetes: A pathophysiologically sound treatment
-
Triplitt, C.; Cersosimo, E.; DeFronzo, R.A. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc. Health Risk Manag., 2010, 6, 671-690.
-
(2010)
Vasc. Health Risk Manag
, vol.6
, pp. 671-690
-
-
Triplitt, C.1
Cersosimo, E.2
DeFronzo, R.A.3
-
36
-
-
77957687159
-
Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists
-
Peng, Y.H.; Coumar, M.S.; Leou, J.S.; Wu, J.S.; Shiao, H.Y.; Lin, C.H.; Lin WH, Lien, T.W.; Chen, X.; Hsu, J.T.; Chao, Y.S.; Huang, C.F.; Lyu PC, Hsieh, H.P.; Wu, S.Y. Structural basis for the improved potency of peroxisome proliferator-activated receptor (PPAR) agonists. Chem. Med. Chem., 2010, 5, 1707-1716.
-
(2010)
Chem. Med. Chem
, vol.5
, pp. 1707-1716
-
-
Peng, Y.H.1
Coumar, M.S.2
Leou, J.S.3
Wu, J.S.4
Shiao, H.Y.5
Lin, C.H.6
Lin, W.H.7
Lien, T.W.8
Chen, X.9
Hsu, J.T.10
Chao, Y.S.11
Huang, C.F.12
Lyu, P.C.13
Hsieh, H.P.14
Wu, S.Y.15
-
37
-
-
67649852314
-
PPAR-alpha and PPAR-gamma agonists for type 2 diabetes
-
Charbonnel, B. PPAR-alpha and PPAR-gamma agonists for type 2 diabetes. Lancet, 2009, 374, 96-98.
-
(2009)
Lancet
, vol.374
, pp. 96-98
-
-
Charbonnel, B.1
-
38
-
-
0036040929
-
Effects of fibrates on serummetabolic parameters
-
Elisaf, M. Effects of fibrates on serummetabolic parameters. Curr. Med. Res. Opin., 2002, 18, 269-276.
-
(2002)
Curr. Med. Res. Opin
, vol.18
, pp. 269-276
-
-
Elisaf, M.1
-
39
-
-
0036094913
-
Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis
-
Barbier, O.; Torra, I.P.; Duguay, Y.; Blanquart, C.; Fruchart, J.C.; Glineur, C.; Staels, B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 717-726.
-
(2002)
Arterioscler. Thromb. Vasc. Biol
, vol.22
, pp. 717-726
-
-
Barbier, O.1
Torra, I.P.2
Duguay, Y.3
Blanquart, C.4
Fruchart, J.C.5
Glineur, C.6
Staels, B.7
-
40
-
-
50649089597
-
Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease
-
Staels, B.; Maes.; M.; Zambon, A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat. Clin. Pract. Cardiovasc. Med., 2008, 5, 542-553.
-
(2008)
Nat. Clin. Pract. Cardiovasc. Med
, vol.5
, pp. 542-553
-
-
Staels, B.1
Maes, M.2
Zambon, A.3
-
41
-
-
34547661569
-
Safety issues and prospects for future generations of PPAR modulators
-
Rubenstrunk, A.; Hanf, R.; Hum, D.W.; Fruchart, J.C.; Staels, B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta, 2007, 1771, 1065-1081.
-
(2007)
Biochim. Biophys. Acta
, vol.1771
, pp. 1065-1081
-
-
Rubenstrunk, A.1
Hanf, R.2
Hum, D.W.3
Fruchart, J.C.4
Staels, B.5
-
42
-
-
47249146946
-
PPAR modulators and PPAR pan agonists for metabolic diseases: The next generation of drugs targeting peroxisome proliferator-activated receptors?
-
Feldman, P.L.; Lambert, M.H.; Henke, B.R. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Curr. Top. Med. Chem., 2008. 8, 728-749.
-
(2008)
Curr. Top. Med. Chem
, vol.8
, pp. 728-749
-
-
Feldman, P.L.1
Lambert, M.H.2
Henke, B.R.3
-
43
-
-
35448951406
-
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist
-
Waites, C.R.; Dominick, M.A.; Sanderson, T.P.; Schilling, B.E. Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist. Toxicol. Sci., 2007, 100, 248-258.
-
(2007)
Toxicol. Sci
, vol.100
, pp. 248-258
-
-
Waites, C.R.1
Dominick, M.A.2
Sanderson, T.P.3
Schilling, B.E.4
-
44
-
-
26844431513
-
Dual and pan-peroxisome proliferatoractivated receptors (PPAR) co-agonism: The bezafibrate lessons
-
Tenenbaum, A.; Motro, M.; Fisman, E.Z. Dual and pan-peroxisome proliferatoractivated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc. Diabetol., 2005, 4, 14.
-
(2005)
Cardiovasc. Diabetol
, vol.4
, pp. 14
-
-
Tenenbaum, A.1
Motro, M.2
Fisman, E.Z.3
-
45
-
-
34548182594
-
PPAR dual agonists: Are they opening Pandora's Box?
-
Balakumar, P.; Rose, M.; Ganti, S.S.; Krishan, P.; Singh, M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol. Res., 2007, 56, 91-98.
-
(2007)
Pharmacol. Res
, vol.56
, pp. 91-98
-
-
Balakumar, P.1
Rose, M.2
Ganti, S.S.3
Krishan, P.4
Singh, M.5
-
46
-
-
79955586140
-
Dual acting and pan-PPAR activators as potential anti-diabetic therapies
-
Heald, M.; Cawthorne, M.A. Dual acting and pan-PPAR activators as potential anti-diabetic therapies. Handb. Exp. Pharmacol., 2011, 203, 35-51.
-
(2011)
Handb. Exp. Pharmacol
, vol.203
, pp. 35-51
-
-
Heald, M.1
Cawthorne, M.A.2
-
47
-
-
60849100836
-
The development of INT131 as a selective PPARc modulator (SPPARM): Approach to a safer insulin sensitizer
-
Higgins, L.S.; Mantzoros, C.M. The development of INT131 as a selective PPARc modulator (SPPARM): approach to a safer insulin sensitizer. PPAR Res., 2008, 2008, 936906.
-
(2008)
PPAR Res
, vol.2008
, pp. 936906
-
-
Higgins, L.S.1
Mantzoros, C.M.2
-
48
-
-
79951671439
-
Pharmacophore-driven identification of PPARγ agonists from natural sources
-
Petersen, R.K.; Christensen, K.B.; Assimopoulou, A.N.; Fretté, X.; Papageorgiou, V.P.; Kristiansen, K.; Kouskoumvekaki, I. Pharmacophore-driven identification of PPARγ agonists from natural sources. J. Comput. Aided Mol. Des., 2011, 25, 107-116.
-
(2011)
J. Comput. Aided Mol. Des
, vol.25
, pp. 107-116
-
-
Petersen, R.K.1
Christensen, K.B.2
Assimopoulou, A.N.3
Fretté, X.4
Papageorgiou, V.P.5
Kristiansen, K.6
Kouskoumvekaki, I.7
-
49
-
-
0033998334
-
The PPARs: From orphan receptors to drug discovery
-
Willson, T.M.; Brown, P.J.; Sternbach, D.D.; Henke, B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem., 2000, 43, 527-550.
-
(2000)
J. Med. Chem
, vol.43
, pp. 527-550
-
-
Willson, T.M.1
Brown, P.J.2
Sternbach, D.D.3
Henke, B.R.4
-
50
-
-
0036090467
-
Divergent effects of selective peroxisome proliferator-activated receptorc-2 ligands on adipocyte versus osteoblast differentiation
-
Lecka-Czernik, B.; Moerman, E.J.; Grant, D.F.; Lehmann, J.M.; Manolagas, S.C.; Jilka, R.L. Divergent effects of selective peroxisome proliferator-activated receptorc-2 ligands on adipocyte versus osteoblast differentiation. Endocrinology, 2002, 143, 2376-2384.
-
(2002)
Endocrinology
, vol.143
, pp. 2376-2384
-
-
Lecka-Czernik, B.1
Moerman, E.J.2
Grant, D.F.3
Lehmann, J.M.4
Manolagas, S.C.5
Jilka, R.L.6
-
51
-
-
74049159051
-
Selective peroxisome proliferatoractivated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation
-
Higgins, L.S.; Depaoli, A.M. Selective peroxisome proliferatoractivated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am. J. Clin. Nutr., 2010, 91, 267S-272S.
-
(2010)
Am. J. Clin. Nutr
, vol.91
-
-
Higgins, L.S.1
Depaoli, A.M.2
-
52
-
-
33750580948
-
Halofenate is a selective peroxisome proliferatoractivated receptor gamma modulator with antidiabetic activity
-
Allen, T.; Zhang, F.; Moodie, S.A.; Clemens, L.E.; Smith, A.; Gregoire, F. Halofenate is a selective peroxisome proliferatoractivated receptor gamma modulator with antidiabetic activity. Diabetes, 2006, 55, 2523-2533.
-
(2006)
Diabetes
, vol.55
, pp. 2523-2533
-
-
Allen, T.1
Zhang, F.2
Moodie, S.A.3
Clemens, L.E.4
Smith, A.5
Gregoire, F.6
-
53
-
-
53149121998
-
Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-gamma Agonist
-
Clarke, H.J.; Gregoire, F.; Ma, F.; Martin, R.; Zhao, S.; Lavan, B.E. Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-gamma Agonist. PPAR Res., 2008, 2008, 465715.
-
(2008)
PPAR Res
, vol.2008
, pp. 465715
-
-
Clarke, H.J.1
Gregoire, F.2
Ma, F.3
Martin, R.4
Zhao, S.5
Lavan, B.E.6
-
54
-
-
67649598394
-
MBX-102/JNJ39659100, a novel peroxisome proliferator activated receptor-ligand with weak transactivation activity retains full anti-diabetic properties in the absence of side effects
-
Gregoire, F.M.; Zhang, F.; Clarke, H.J.; Gustafson, T.A.; Sears, D.D.; Favelyukis, S.; Lenhard, J.; Rentzeperis, D.; Clemens, L.E.; Mu, Y.; Lavan, B.E. MBX-102/JNJ39659100, a novel peroxisome proliferator activated receptor-ligand with weak transactivation activity retains full anti-diabetic properties in the absence of side effects. Mol. Endocrinol., 2009, 23, 975-988.
-
(2009)
Mol. Endocrinol
, vol.23
, pp. 975-988
-
-
Gregoire, F.M.1
Zhang, F.2
Clarke, H.J.3
Gustafson, T.A.4
Sears, D.D.5
Favelyukis, S.6
Lenhard, J.7
Rentzeperis, D.8
Clemens, L.E.9
Mu, Y.10
Lavan, B.E.11
-
55
-
-
33645394377
-
Novel partial agonist of peroxisome proliferatoractivated receptor-gamma (PPARgamma) recruits PPARgammacoactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro
-
Burgermeister, E.; Schnoebelen, A.; Flament, A.; Benz, J.; Stihle, M.; Gsell, B. A. novel partial agonist of peroxisome proliferatoractivated receptor-gamma (PPARgamma) recruits PPARgammacoactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol. Endocrinol., 2006, 20, 809-830.
-
(2006)
Mol. Endocrinol
, vol.20
, pp. 809-830
-
-
Burgermeister, E.1
Schnoebelen, A.2
Flament, A.3
Benz, J.4
Stihle, M.5
Gsell, B.A.6
-
56
-
-
60849095073
-
INT131: A selective modulator of PPAR gamma
-
Motani, A.; Wang, Z.; Weiszmann, J.; McGee, L.R.; Lee, G.; Liu, Q.; Staunton, J.; Fang, Z.; Fuentes, H.; Lindstrom, M.; Liu, J.; Biermann, D.H.; Jaen, J.; Walker, N.P.; Learned, RM.; Chen, J.L.; Li, Y. INT131: a selective modulator of PPAR gamma. J. Mol. Biol., 2009, 386, 1301-1311.
-
(2009)
J. Mol. Biol
, vol.386
, pp. 1301-1311
-
-
Motani, A.1
Wang, Z.2
Weiszmann, J.3
McGee, L.R.4
Lee, G.5
Liu, Q.6
Staunton, J.7
Fang, Z.8
Fuentes, H.9
Lindstrom, M.10
Liu, J.11
Biermann, D.H.12
Jaen, J.13
Walker, N.P.14
Learned, R.M.15
Chen, J.L.16
Li, Y.17
-
57
-
-
1542547460
-
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
-
Benson, S.C.; Pershadsingh, H.A.; Ho, C.I.; Chittiboyina, A.; Desai, P.; Pravenec, M.; Qi, N.; Wang, J.; Avery, M.A.; Kurtz, T.W. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension, 2004, 43, 993-1002.
-
(2004)
Hypertension
, vol.43
, pp. 993-1002
-
-
Benson, S.C.1
Pershadsingh, H.A.2
Ho, C.I.3
Chittiboyina, A.4
Desai, P.5
Pravenec, M.6
Qi, N.7
Wang, J.8
Avery, M.A.9
Kurtz, T.W.10
-
58
-
-
33644858190
-
Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma
-
Pershadsingh, H.A. Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma. Int. J. Biochem. Cell Biol., 2006, 38, 766-781
-
(2006)
Int. J. Biochem. Cell Biol
, vol.38
, pp. 766-781
-
-
Pershadsingh, H.A.1
-
59
-
-
2442451618
-
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity
-
Schupp, M.; Janke, J.; Clasen, R.; Unger, T.; Kintscher, U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation, 2004, 109, 2054-2057.
-
(2004)
Circulation
, vol.109
, pp. 2054-2057
-
-
Schupp, M.1
Janke, J.2
Clasen, R.3
Unger, T.4
Kintscher, U.5
-
60
-
-
79955032219
-
Telmisartan: A review of its use in cardiovascular disease prevention
-
Frampton, J.E. Telmisartan: a review of its use in cardiovascular disease prevention. Drugs, 2011, 71, 651-677.
-
(2011)
Drugs
, vol.71
, pp. 651-677
-
-
Frampton, J.E.1
-
61
-
-
11144313062
-
Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property
-
Yamagishi, S.; Takeuchi, M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med. Hypotheses, 2005, 64, 476-478.
-
(2005)
Med. Hypotheses
, vol.64
, pp. 476-478
-
-
Yamagishi, S.1
Takeuchi, M.2
-
62
-
-
33745982069
-
Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in dietinduced obese mice
-
Araki, K.; Masaki, T.; Katsuragi, I.; Tanaka, K.; Kakuma, T.; Yoshimatsu, H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in dietinduced obese mice. Hypertension, 2006, 48, 51-57.
-
(2006)
Hypertension
, vol.48
, pp. 51-57
-
-
Araki, K.1
Masaki, T.2
Katsuragi, I.3
Tanaka, K.4
Kakuma, T.5
Yoshimatsu, H.6
-
63
-
-
79953721690
-
Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension
-
Bekki, H.; Yamamoto, K.; Sone, M.; Homma, T.; Nakata, M.; Nohara, M.; Fukami, K.; Okuda, S.; Yamagishi, S. Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension. Clin. Cardiol., 2011, 34, 261-265.
-
(2011)
Clin. Cardiol
, vol.34
, pp. 261-265
-
-
Bekki, H.1
Yamamoto, K.2
Sone, M.3
Homma, T.4
Nakata, M.5
Nohara, M.6
Fukami, K.7
Okuda, S.8
Yamagishi, S.9
-
64
-
-
0033625677
-
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)
-
Peters, J.M.; Lee, S.S.; Li, W.; Ward, J.M.; Gavrilova, O.; Everett, C.; Reitman, M.L.; Hudson, L.D.; Gonzalez, F.J. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta). Mol. Cell. Biol., 2000, 20, 5119-5128.
-
(2000)
Mol. Cell. Biol
, vol.20
, pp. 5119-5128
-
-
Peters, J.M.1
Lee, S.S.2
Li, W.3
Ward, J.M.4
Gavrilova, O.5
Everett, C.6
Reitman, M.L.7
Hudson, L.D.8
Gonzalez, F.J.9
-
65
-
-
0033599038
-
Dominant negative mutations in human PPARmmassociated with severe insulin resistance, diabetes mellitus and hypertension
-
Barroso, I.; Gurnell, M.; Crowley, V.E.; Agostini, M.; Schwabe, J.W.; Soos, M.A.; Maslen, G.L.; Williams, T.D.; Lewis, H.; Schafer, A.J.; Chatterjee, V.K.; O'Rahilly, S. Dominant negative mutations in human PPARmmassociated with severe insulin resistance, diabetes mellitus and hypertension. Nature, 1999, 402, 880-883.
-
(1999)
Nature
, vol.402
, pp. 880-883
-
-
Barroso, I.1
Gurnell, M.2
Crowley, V.E.3
Agostini, M.4
Schwabe, J.W.5
Soos, M.A.6
Maslen, G.L.7
Williams, T.D.8
Lewis, H.9
Schafer, A.J.10
Chatterjee, V.K.11
O'Rahilly, S.12
-
66
-
-
79955420151
-
The Role Played by the Peroxisome Proliferator-Activated Receptor-P///PPARP///Activator, GW501516, in Control of Fatty Acid Metabolism: A New Potential Therapeutic Target for Treating Metabolic Syndrome
-
Lee, J.; Chung, W.Y. The Role Played by the Peroxisome Proliferator-Activated Receptor-P///PPARP///Activator, GW501516, in Control of Fatty Acid Metabolism: A New Potential Therapeutic Target for Treating Metabolic Syndrome. Endocrinology, 2011, 152, 1742-1744.
-
(2011)
Endocrinology
, vol.152
, pp. 1742-1744
-
-
Lee, J.1
Chung, W.Y.2
-
67
-
-
13844314826
-
Herbal or natural medicines as modulators of peroxisome proliferatoractivated receptors and related nuclear receptors for therapy of metabolic syndrome
-
Huang, T.H.; Kota, B.P.; Razmovski, V.; Roufogalis, B.D. Herbal or natural medicines as modulators of peroxisome proliferatoractivated receptors and related nuclear receptors for therapy of metabolic syndrome. Basic Clin. Pharmacol. Toxicol., 2005, 96, 3-14.
-
(2005)
Basic Clin. Pharmacol. Toxicol
, vol.96
, pp. 3-14
-
-
Huang, T.H.1
Kota, B.P.2
Razmovski, V.3
Roufogalis, B.D.4
-
68
-
-
79959536439
-
Laboratory studies on weight control and prevention of metabolic syndrome by green tea
-
Sae-Tan, S.; Grove, K.A.; Lambert, J.D. Laboratory studies on weight control and prevention of metabolic syndrome by green tea. Pharmacol. Res., 2011, 64, 146-154.
-
(2011)
Pharmacol. Res
, vol.64
, pp. 146-154
-
-
Sae-Tan, S.1
Grove, K.A.2
Lambert, J.D.3
-
69
-
-
45549102505
-
Effects of green tea on insulin sensitivity, lipid profile and expression of pparalpha and ppargamma and their target genes in obese dogs
-
Serisier, S.; Leray, V.; Poudroux, W.; Magot, T.; Ouguerram, K.; Nguyen, P. Effects of green tea on insulin sensitivity, lipid profile and expression of pparalpha and ppargamma and their target genes in obese dogs. Br. J. Nutr., 2008, 99, 1208-1216.
-
(2008)
Br. J. Nutr
, vol.99
, pp. 1208-1216
-
-
Serisier, S.1
Leray, V.2
Poudroux, W.3
Magot, T.4
Ouguerram, K.5
Nguyen, P.6
-
70
-
-
79951795388
-
Chinese herbal extracts (SK0506) as a potential candidate for the therapy of the metabolic syndrome
-
Tan, Y.; Kamal.; M.A.; Wang, Z.Z.; Xiao, W.; Seale, J.P.; Qu, X. Chinese herbal extracts (SK0506) as a potential candidate for the therapy of the metabolic syndrome. Clin. Sci. (Lond), 2011, 120, 297-305.
-
(2011)
Clin. Sci. (Lond)
, vol.120
, pp. 297-305
-
-
Tan, Y.1
Kamal, M.A.2
Wang, Z.Z.3
Xiao, W.4
Seale, J.P.5
Qu, X.6
-
71
-
-
33749336146
-
Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states
-
Lee, Y.S.; Kim, W.S.; Kim, K.H.; Yoon, M.J.; Cho, H.J.; Shen, Y.; Ye, J.M.; Lee, C.H.; Oh, WK.; Kim, C.T.; Hohnen-Behrens, C.; Gosby, A.; Kraegen, E.W.; James, D.E.; Kim, J.B. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes, 2006, 55, 2256-2264.
-
(2006)
Diabetes
, vol.55
, pp. 2256-2264
-
-
Lee, Y.S.1
Kim, W.S.2
Kim, K.H.3
Yoon, M.J.4
Cho, H.J.5
Shen, Y.6
Ye, J.M.7
Lee, C.H.8
Oh, W.K.9
Kim, C.T.10
Hohnen-Behrens, C.11
Gosby, A.12
Kraegen, E.W.13
James, D.E.14
Kim, J.B.15
-
72
-
-
79951808906
-
Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice
-
Halade, G.V.; Williams, P.J.; Lindsey, M.L. Fernandes, G. Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice. Pharmacol. Res., 2011, 63, 300-307.
-
(2011)
Pharmacol. Res
, vol.63
, pp. 300-307
-
-
Halade, G.V.1
Williams, P.J.2
Lindsey, M.L.3
Fernandes, G.4
-
73
-
-
42449125303
-
Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists?
-
Gani, O.A. Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists? Cardiovasc. Diabetol., 2008, 20, 7, 6.
-
(2008)
Cardiovasc. Diabetol
, vol.20
-
-
Gani, O.A.1
|